A merger between Proterris and Alfama will allow the companies to continue development of carbon monoxide therapy for acute and chronic diseases, according to PulmonaryFibrosisNews.com.
Proterris has acquired Alfama’s Carbon Monoxide-Releasing Molecules (CORMs). These molecules can expand the application of carbon monoxide not only to the inhaled form but also to orally or injectable formulations, addressing conditions where inhaled CO may not be suitable.
Research studies show carbon monoxide has the potential to modulate inflammatory processes, to protect cells from damage caused by oxygen reactive elements, and to have anti-proliferative activity. Because of these features, carbon monoxide can be a qualified agent to protect tissues from damage in many acute and chronic medical conditions.
